Assessing Zealand Pharma (CPSE:ZEAL) Valuation After New AI-Focused Cambridge Research Hub Announcement

Zealand Pharma (CPSE:ZEAL) recently announced a new research hub in Cambridge, Massachusetts. This facility will become its primary U.S. base and will focus on AI-driven drug discovery, advanced automation, and new therapeutic modalities.

See our latest analysis for Zealand Pharma.

The share price is DKK298.0 after a 1-day share price return of 1.02% and a 7-day share price return of 3.47%. However, the 30-day and year-to-date share price returns of -19.28% and -35.23% suggest recent momentum has been weak, even though the 3-year and 5-year total shareholder returns of 40.57% and 43.68% point to a stronger longer-term record.

If Zealand Pharma’s AI push has caught your attention, this could be a good moment to look across the sector and check out 125 healthcare AI stocks

With the share price well below the consensus analyst target, and recent returns weaker than the 3 and 5 year track record, the key question is whether Zealand Pharma is now on sale or if markets are already pricing in future growth.

Most Popular Narrative: 51.2% Undervalued

With Zealand Pharma’s fair value narrative at DKK610.79 against a last close of DKK298.00, the current price sits well below that assessment. This view hinges heavily on how its obesity pipeline and partnership economics play out.

The updated analyst price target for Zealand Pharma moves lower to DKK 611 from about DKK 730, as analysts factor in reduced expectations for petrelintide’s obesity opportunity, modestly higher risk assumptions, and a lower implied future P/E multiple, following a series of rating downgrades to Neutral or Hold.

Recent research notes cluster around a more cautious stance on Zealand Pharma, with several firms shifting ratings to Neutral or Hold and setting price targets below the prior DKK 730 level. The common thread is a reassessment of petrelintide’s role in obesity treatment and how that may flow through to valuation and execution risk.

Read the complete narrative.

Want to see why a lowered growth outlook can still support a higher fair value than today? The narrative leans on future earnings power, margin assumptions and a richer profit multiple than the current market is implying.

Result: Fair Value of DKK610.79 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this depends on obesity trial outcomes and intense competition, where weaker efficacy data or pricing pressure could quickly undermine the current upside narrative.

Find out about the key risks to this Zealand Pharma narrative.

Next Steps

With sentiment clearly split between risks and rewards, it makes sense to look at the details yourself and act before opinions settle. To weigh both sides, start with 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Zealand Pharma is on your radar, this is a great time to broaden your watchlist with other focused ideas that match different styles and priorities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com